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Abstract: 
Background: Animal studies suggest that the antibiotic and microglial activation 
inhibitor, minocycline, is likely to have a protective effect against the emergence of 
psychosis but evidence from human studies is lacking. The aim of this study is to 
examine the effects of exposure to minocycline during adolescence on the later 
incidence of severe mental illness (SMI). 
Methods:  A historical cohort study using electronic primary care data was conducted 
to assess the association between exposure to minocycline during adolescence and 
incidence of SMI. The Incidence Rate Ratio (IRR) was measured using Poisson 
regression adjusted for age, gender, time of exposure, socioeconomic deprivation status, 
calendar year and co-medications. 
Results: Early minocycline prescription (n=13 248) did not affect the incidence of SMI 
compared with non-prescription of minocycline (n=14 393), regardless of gender or 
whether or not the data were filtered according to a minimum exposure period 
(minimum period - IRR 0.96; 95% CI 0.68-1.36; p=0.821; no minimum period - IRR 
1.08; 95% CI 0.83-1.42; p=0.566). 
Conclusions: Exposure to minocycline for acne treatment during adolescence appears 
to have no effect on the incidence of SMI. 
Key words: schizophrenia/drug repurposing/preventive effect/tetracycline  
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Introduction 
There is accumulating evidence to suggest that neuroinflammation arising from 
activation of microglia plays an important role in the aetiology of severe mental 
illnesses (SMI) such as schizophrenia, bipolar depression, or other psychotic 
conditions (Takahashi et al., 2016). It has been proposed that the therapeutic 
effect of atypical antipsychotics may be related to the reduction of the microglial 
inflammatory response (Monji et al., 2013), fuelling the hypothesis that control 
of microglial activation could provide a promising therapeutic strategy for 
management of psychosis (Keller et al., 2013). The second generation tetracycline 
minocycline, a known inhibitor of microglial activation (Zhang and Zhao, 2014), 
has been postulated as a promising adjuvant therapy to antipsychotics and its 
potential beneficial effects have been assessed in various clinical trials (Chaudhry 
et al., 2012; Chaves et al., 2015; Ghanizadeh et al., 2014; Husain et al., 2017; Kelly 
et al., 2015; Khodaie-Ardakani et al., 2014; Levkovitz et al., 2010; Liu et al., 2014; 
Miyaoka et al., 2012). These clinical trials were conducted using very different 
study designs, however, and the results differed considerably (Oya et al., 2014). 
Although they showed evidence of a beneficial effect of adjuvant therapy with 
minocycline in negative symptoms of schizophrenia and related disorders, the 
small populations and short lengths of study periods were common limitations 
(Xiang et al., 2016). A preventative effect of minocycline – i.e., exposure before 
the onset of the disease −  has also been hypothesised but tested only in animal 
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models (Levkovitz et al., 2007; Monte et al., 2013; Zhang et al., 2007). Recently, 
Giovanoli et al. (2016) postulated that attenuation of inflammatory reactions in 
peri-pubertal stress exposure could prevent the adult onset of behavioural 
pathologies and conducted investigations to determine whether pre-symptomatic 
administration of minocycline could prevent the emergence of behavioural 
abnormalities, concluding that minocycline had a preventative effect on 
sensorimotor gating and psychosomatic drug sensitivity in animals but failed to 
prevent the stress-induced increase in anxiety-like behaviour. A preventative 
effect of minocycline, however, has not been evaluated in clinical or 
epidemiological studies. In past years, minocycline was widely used as the first 
line oral antibiotic for treatment of acne, but its use over the last decade has fallen 
due to safety and cost concerns (Garner et al., 2003). Although minocycline’s use 
to treat acne is not recommended by NICE Clinical Knowledge Summaries 
(National Institute for Health and Care Excellence, 2014), it is still used primarily 
for this indication (National Institute for Health and Care Excellence, 2015) 
which usually starts in adolescence and frequently resolves by early twenties, 
being most prevalent in individuals aged 15-24 years (Zaenglein et al., 2016). 
Here, we present the first historical cohort study using primary care electronic 
data to investigate whether exposure to minocycline during adolescence in 
individuals diagnosed with acne is associated with a reduced incidence of SMI. 
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Methods 
Study Design and Population 
A historical cohort study was conducted using data from the Clinical Practice 
Research Datalink database (CPRD; https://www.cprd.com), a well-established 
United Kingdom (UK) primary care research database of electronic health 
records (García Rodríguez and Pérez Gutthann, 2002; Herrett et al., 2010). As 
primary care is free at the point of delivery, it has almost universal coverage in 
the UK. The database has been described in detail elsewhere (Williams et al., 
2012). 
The study protocol was reviewed and approved by the Independent Scientific 
Advisory Committee (ISAC) for Medicines and Healthcare products Regulatory 
Agency (MHRA) Database Research (ISAC protocol number 15_245A2, June 
2016). 
Selection of Minocycline Users and the Comparison Group 
The study population comprised those patients with one or several recorded 
diagnoses of acne (Supplementary Table 1) at the ages of 15 to 20 years old 
(inclusive) during the years 1991 to 2005. To avoid potential bias from missing 
data, only patients with twelve or more months registration before a diagnosis of 
acne in the CPRD were included.  The study population was divided into an 
exposed cohort (those individuals treated with oral minocycline) and a control 
cohort (those individuals prescribed oral acne antibiotics for moderate or severe 
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acne other than minocycline: lymecycline, tetracycline, oxytetracycline or 
erythromycin). Exposure was identified as recorded prescriptions of these drugs 
in the CPRD database (Supplementary Tables 2a,b). Patients with a recorded 
prescription of any of these drugs before the diagnosis of acne were not included 
in the study. 
The start of the follow-up period for all patients was the date of the first 
completion of a minimum continuous treatment with minocycline or alternative 
treatment (Figure 1). Patients with any recorded prescription of isotretinoin – a 
retinoid used to treat moderate and severe acne that has been linked to adverse 
psychiatric reactions in several reports (Ludot et al., 2015) − or any recorded 
prescription of  an antipsychotic drug prior to the start of follow-up were not 
included in the study. 
 
[Insert Figure 1] 
Figure 1. Example of the follow-up period of a patient exposed to minocycline (exposed 
cohort) in the primary and sensitivity analyses 
The follow-up period ended at the earliest of the following: the date the patient 
left the practice, death date, the latest date of data collection (January 2016), or 
the earliest date of a diagnosis of SMI (outcome). Individuals prescribed an 
alternative treatment as first-line option were considered controls until they were 
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prescribed minocycline, when the follow-up as control individuals was stopped. 
They switched to the exposed cohort if a minimum treatment with minocycline 
was completed (Figure 2). For patients who were prescribed an alternative 
treatment after being exposed to minocycline, follow-up was continued in the 
exposed cohort. All individuals were censored if they had a recorded prescription 
of isotretinoin after the start of follow-up date. 
 
[Insert Figure 2] 
 Figure 2. Example of the end of follow-up as a control cohort individual and the start of 
follow-up period as an exposed cohort individual in the primary and sensitivity analyses. 
In the primary analysis, the date of the start of follow-up is the completion of a minimum 
duration of treatment with an alternative drug or minocycline and the dates of the end of 
follow-up as a control individual and the start of follow-up as an exposed individual 
cannot overlap. In the sensitivity analysis, there is not a minimum duration of treatment 
and the dates of the stop of follow-up as control individual and the start of follow-up as 
exposed individual will coincide. 
 
Definition of Exposure 
The primary analysis considered a minimum duration of exposure to minocycline 
(42 days) or the alternative treatments equal to the recommended minimum 
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duration of treatment with these drugs for the treatment of acne − based on the 
information of the drugs’ Summary of Product Characteristics, the British 
National Formulary (British National Formulary, 2016) or the NICE guidelines 
(National Institute for Health and Care Excellence, 2016). Duration of treatment 
was calculated using the recorded information for the total quantity for the 
prescribed product and the numeric daily dose prescribed for the event. Where 
this information was missing (8.3% of prescriptions had missing information), 
the mean obtained from all other prescriptions of the same drug product was 
imputed. Continuous or discontinuous exposure was calculated by considering 
the starting date for individual prescriptions and their duration of treatment and 
accounting for overlapping prescriptions or temporal gaps, respectively (Figure 
1). A temporal gap of up to seven days was considered as continuous use. 
 
Identification of Patients with Severe Mental Illness (SMI) 
The outcome for this study was the first recording of a diagnosis of SMI identified 
using the validated Severe Mental Illnesses codes list created by Hardoon et al. 
(2013), which classifies codes as schizophrenia, bipolar and other psychotic 
disorders (Supplementary Table 4). Individuals with any recorded diagnosis of 
SMI before the start of the follow-up period were not included in the study. 
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Sensitivity Analysis 
A sensitivity analysis was conducted where a minimum duration of treatment was 
not established and therefore, the follow-up period was taken to start at the first 
prescription of minocycline or alternative antibiotics. Patients in the control 
cohort were switched to the exposed cohort at the date of receipt of a minocycline 
prescription (Figure 2). 
Both the primary and sensitivity analyses were adjusted for covariables: age, 
gender, time of exposure to minocycline or alternative drugs, socioeconomic 
deprivation status, calendar year and exposure to co-medications measured at the 
start of follow-up. Socioeconomic deprivation status, which has been described 
to have a potential relationship with the incidence of SMI (Kirkbride et al., 2012), 
was represented as the practice Index of Multiple Deprivation (IMD) score, the 
official measure of relative deprivation for small areas in England. Multiple 
deprivation is articulated as an accumulation of discrete dimensions of 
deprivation such as financial, health, education, services or crime. In this study 
the practice IMD, which uses the general practice postcode and data, was 
provided as quintiles of the deprivation score or rank to prevent disclosure of 
practice area. Co-medications of interest were those agents potentially related to 
the incidence of SMI and are listed in Table 1. 
In separate analyses, we investigated the potential relationship with 1) gender, 2) 
exposure to doxycycline, or 3) type of SMI diagnoses, whilst considering a 
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minimum duration of treatment (as per primary analysis). The potential 
relationship between gender and incidence of schizophrenia, which has been 
observed to be higher in young men than women (Castle et al., 2000), was 
analysed by stratifying the analyses based on gender. To assess the potential 
relationship between the incidence of SMI and exposure to doxycycline, which is 
chemically similar to minocycline and can also penetrate the blood-brain barrier 
(Domercq and Matute, 2004), we conducted a sensitivity analysis with two main 
treatment options: minocycline and doxycycline (exposed cohort) and 
tetracycline, lymecycline, oxytetracycline and erythromycin (control cohort). All 
prescriptions of these drugs were considered as continuous treatment if they 
overlapped or finished and started on consecutive days, allowing for a treatment 
gap up to 7 days. Finally, we assessed the relationship between minocycline and 
schizophrenia specifically, defining the output as the first recorded diagnosis of a 
schizophrenia-related code only. 
Results 
The total number of individuals with at least one recorded acne diagnosis at ages 
15-20 years old between 1991 and 2005 and at least twelve months of recorded 
CPRD data was 61 744, of whom 25 288 were female (41%) and 36 456 male 
(59%). 19 903 individuals (32%) had a recorded prescription of minocycline 
(6392) and or alternative oral antibiotic (16 057) before the first diagnosis of acne 
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after at least 12 months of recorded follow-up on the CPRD and were not included 
in the study. From the remaining 41 841 individuals, 4930 (11.8%) were 
prescribed minocycline but never an alternative treatment; 27 484 (65.7%) 
individuals were prescribed an alternative treatment but never minocycline; and 
9427 (22.5%) individuals were prescribed both. 
 
[Insert Figure 3] 
Figure 3. Construction of the study cohorts in the primary and sensitivity analyses. 
After the application of inclusion and exclusion criteria in the primary analysis 
(Figure 3), the final number of individuals in the control and exposed cohorts 
were 13 248 and 14 393, respectively. The distributions of men and women were 
36.6% females and 63.4% males in the control cohort, and 34.6% females and 
65.4% males in the exposed cohort.  
The average follow-up time in the control cohort (6.53 years) and in the exposed 
cohort (8.95 years) was statistically significantly different (t test, p<0.001). 
46.64% of all patients in the minocycline-exposed group (n = 6180) and 38.93% 
(n = 5604) of those prescribed an alternative treatment for acne were followed up 
from the start date until the final data collection date. 45.75% percent of all study 
participants (6849 individuals exposed to minocycline and 5798 individuals in 
the control cohort) were followed up until they transferred to another primary 
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care practice, while 0.23% of individuals were followed up until their recorded 
death date. Follow-up was stopped for 2816 (19.57%) individuals in the control 
cohort when prescribed minocycline, while 108 (0.82%) and 84 (0.58%) in the 
exposed and control cohorts, respectively, were censored when prescribed 
isotretinoin.  Characteristics of the individuals in the two cohorts and their 
standardised differences (Austin, 2009) are presented in Table 1, while the 
median duration of exposure to minocycline or alternative treatment in the 
primary analysis are shown in Table 2. 
Table 1. Characteristics of the individuals in the exposed and control cohorts presented 
as number of individuals (n) and percentages. (IMD: Practice Index of Multiple 
Deprivation being IMD1 = least deprived and IMD5 = more deprived). Standardised 
differences greater than 0.1 (*) are considered meaningful. 
Characteristics Minocycline-
exposed individuals 
(n=13 248) 
Alternative treatment-
exposed individuals 
(n=14 393) 
Standardised 
differences 
Median age at start-date 17.42 ± 5.17 17.61 ± 7.99 0.074 
Sex, n (%) 
Male 8405 (63.4) 9418 (65.4) 0.042 
Female 4843 (36.6) 4975 (34.6) 0.042 
Calendar year at start date, n (%) 
1987-1991 573 (4.33) 533 (3.7) 0.032 
1992-1996 3010 (22.72) 2122 (14.74) 0.206* 
1997-2001 3581 (27.03)  3774 (26.22) 0.018 
2002-2006 5455 (41.18) 6353 (44.14) 0.060 
2007-2011 592 (4.47) 1286 (8.93) 0.179* 
2012-2015 37 (0.23) 325 (2.26) 0.184* 
Deprivation status, n (%) 
IMD1 2534 (19.1) 3013 (20.9) 0.045 
IMD2 2554 (19.3) 2802 (19.5) 0.005 
IMD3 2350 (17.3) 2809 (19.5) 0.057 
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IMD4 2721 (20.5) 2729 (19.0) 0.038 
IMD5 3089 (23.3) 3040 (21.1) 0.053 
Exposure to co-medications, n (%) 
aspirin 172 (1.3)  167 (1.16) 0.013 
celecoxib 8 (0.06) 11 (0.08) 0.008 
methotrexate 5 (0.04) 1 (0.01) 0.019 
methylphenidate 32 (0.24) 35 (0.24) 0.000 
metoclopramide 383 (2.89) 416 (2.89) 0.000 
warfarin 7 (0.05) 5 (0.04) 0.005 
hormonal treatment 1,484 (11.21) 1,744 (12.12) 0.028 
antidepressants, hypnotics 
and sedatives 
247 (1.86) 292 (2.03) 0.012 
 
In the primary analysis, the crude incidence rate (IR) of SMI in the minocycline-
exposed cohort was 6.65 per 10,000 person-years (95% confidence interval [CI] 
5.33-8.28) and 6.39 per 10,000 person-years (95% CI 4.96-8.22) in the 
alternative treatment cohort. The crude IRR showed no evidence of a relationship 
between the use of minocycline and the incidence of SMI (IRR 1.04, 95% CI 0.74-
1.46, p=0.816), which was consistent with the results from the analysis adjusted 
for covariables (IRR 0.96, 95% CI 0.68-1.36, see Table 3). 
Table 2. Median duration of treatment in days and interquartile range (IQR) with any 
treatment (overall) and depicted by minocycline or alternative acne treatments in the 
exposed and control cohorts in the primary analysis. 
 
Treatment 
Continuous treatmenta 
Median (IQR) 
Total duration of exposureb 
Median (IQR) 
Ex
p
o
se
d
 c
o
h
o
rt
 Overall 56 (50) 279 (442) 
Minocycline 56 (55) 336 (469) 
Doxycycline 29 (54) 168 (321) 
Lymecycline 56 (44) 202 (322) 
Oxytetracycline 45 (32) 170 (273) 
Tetracycline 32.5 (28) 168 (342) 
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Erythromycin 28 (49) 164 (280) 
C
o
n
tr
o
l c
o
h
o
rt
 
Overall 56 (62) 376 (476) 
Minocycline - - 
Doxycycline 56 (64) 312 (477) 
Lymecycline 58 (55) 403 (495) 
Oxytetracycline 60 (64) 396 (478) 
Tetracycline 56 (70) 358 (400) 
Erythromycin 50 (46) 222 (295) 
a Days exposed to the drug as defined by one recorded prescription. 
b The sum of different exposure periods recorded as different but overlapping recorded prescriptions of the same 
active ingredient. 
 
In the sensitivity analysis, the final number of individuals in the control and 
exposed cohorts was 32 219 (61.3% male) and 14 071 (63.1% male), respectively 
(Figure 3). The mean duration of follow-up was 6.7 years in the control cohort 
and 9.1 years in the exposed cohort. The IR of SMI in the minocycline-exposed 
cohort was 6.9 per 10,000 person-years (95% CI 5.61-8.52) and 6.31 per 10,000 
person-year (95% CI 5.35-7.43) in the alternative treatment cohort. As shown in 
Table 3, the IRR showed no evidence of an association between the use of 
minocycline and the incidence of SMI, even when adjusting for all covariables 
(IRR 1.08, 95% CI 0.83-1.42, p=0.566). 
Gender analyses showed no relationship between treatment with minocycline 
and incidence of SMI either for males or females when adjusted for covariables, 
in the same way that the analysis considering recorded diagnoses of 
schizophrenia-related codes only did not show evidence of a relationship between 
exposure to minocycline and schizophrenia (Table 3). Similar results were 
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obtained when recorded prescriptions of minocycline and doxycycline were 
considered as the drugs of interest (Table 3). 
Detailed results for all the adjusted analyses are shown in Supplementary Table 
8a-f. A relationship between gender (as a covariable) and incidence of SMI was 
observed in the primary, sensitivity and doxycycline-minocycline analyses 
(Supplementary Table 6a,b,d). A higher incidence of SMI was related to individuals 
exposed to acne treatment (in both the exposed and control cohorts) for up to one 
year in the sensitivity and doxycycline-minocycline analyses (Supplementary 
Table 6b,e). A relationship with socioeconomic deprivation status was observed 
only when considering exposed individuals to those prescribed doxycycline 
and/or minocycline (Supplementary Table 6e). 
Table3. Incidence Rate Ratio (IRR) of severe mental illness (SMI) in the different 
analyses adjusted for covariables (age, gender, time of exposure, calendar year, 
socioeconomic deprivation status and co-medications). 
 Person Years SMI Cases Adjusted IRR for covariables (95% CI) 
Primary analysis (minimum duration of treatment) 
Alternative treatment 93 961 60 1 
Minocycline 118 891 79 
0.96 (0.68-1.36) 
p=0.821 
Sensitivity analysis (no minimum duration of treatment) 
Alternative treatment 225 164 142 1 
Minocycline 127 332 88 
1.08 (0.83-1.42) 
p=0.566 
Gender analysis: Males 
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Alternative treatment 64 624 48 1 
Minocycline 78 527 60 
0.94 (0.63-1.38) 
p=0.738 
Gender analysis: Females 
Alternative treatment 29 291 12 1 
Minocycline 40 364 19 
1.10 (0.52-2.32) 
p=0.807 
Doxycycline and/or minocycline 
Alternative treatment* 131 838 79 1 
Doxycycline/minocycline 145 059 96 
1.15 (0.85-1.56) 
p=0.364 
Diagnosis: Schizophrenia 
Alternative treatment 94 202 14 1 
Minocycline 119 217 35 
1.67 (0.89-3.15) 
p=0.111 
*Alternative treatments: tetracycline (oral), lymecycline (oral), oxytetracycline (oral), erythromycin (oral). 
 
Discussion 
Main Findings 
Our study shows no evidence to support a preventative effect of exposure to 
minocycline during adolescence on the incidence of SMI in humans. These 
conclusions were consistent irrespective of considering a minimum duration of 
treatment and did not differ when ruling out the effect of the similar tetracycline 
doxycycline or when considering only schizophrenia-related diagnoses. 
To the best of our knowledge, this is the only study that retrospectively assessed 
the relationship between exposure to minocycline and the incidence of SMI in a 
large population and over a long study period. Minocycline was for a long time 
the first line treatment for moderate and severe acne and, therefore, acne 
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diagnosed patients represent an appropriate population to assess the effects of 
long-term exposure to minocycline while allowing for the identification of a 
control group as those patients prescribed an alternative oral antibiotic, which 
include oral tetracyclines (tetracycline, oxytetracycline, doxycycline, and 
lymecycline) and oral erythromycin. Age 15-20 years is the more likely age for 
acne diagnosis and treatment (Zaenglein et al., 2016) whilst the onset of SMI 
occurs usually later in early adulthood. Hence, these individuals were selected in 
this study to focus on the potential effect of minocycline in adolescence and to 
reduce confounding by treatment with other substances. 
The comparison of baseline covariables using absolute standardised mean 
differences shows the similarity of the two cohorts. Although there is no 
universally accepted threshold to indicate the presence of meaningful imbalance 
(Austin, 2009), only three groups of the stratification of calendar year showed a 
value higher than the typically accepted 0.1 threshold (although they remained ≤ 
0.2). These differences might reflect a change in the prescribers’ preferences 
towards minocycline or alternative treatments, but the adjusted analyses showed 
no impact in the conclusion of this study (Supplementary Table 8). Results were 
adjusted for all mentioned covariables: age, gender, socioeconomic deprivation 
status, time of exposure to minocycline or the alternative treatment, calendar 
year and co-medications described to have a potential relationship with SMI. 
 
 
 
18 
 
Although there is not conclusive evidence of the link between exposure and SMI, 
we adjusted for co-medications described to have a potentially beneficial effect 
on SMI similar to minocycline: warfarin (Hoirisch-Clapauch and Nardi, 2013), 
estrogens in the form of combined oral contraceptives (Bump et al., 2013), 
methotrexate (Chaudhry et al., 2015) and the NSAIDs celecoxib (Akhondzadeh et 
al., 2007) and aspirin (Laan et al., 2010). Those drugs described to potentially 
worsen the symptoms of SMI were also considered: isotretinoin (Ludot et al., 
2015), methylphenidate (Shyu et al., 2015) and metoclopramide (Lu et al., 2002). 
We also adjusted for medications that might be indicative of current psychiatric 
problems – such as prescription of antidepressants, hypnotics or sedatives. 
Regarding gender, the distribution of men and women were similar in the two 
cohorts, with a larger number of males in both groups, which might be explained 
by the selection of alternatives to oral antibiotics, such as hormonal treatments 
as a first line treatment of acne in young women, or the wish to avoid systemic 
treatments in females of childbearing age.  
Patients in the minocycline exposed group had a slightly longer average follow-
up time. We believe this difference in follow-up time occurred because it was 
possible for control group patients to move to the minocycline control group. 
Minocycline exposed group patients remained in their assigned cohort arm, 
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irrespective of any change in treatment for acne, as no protective effect of non-
minocycline antibiotic treatment was expected. 
Although other tetracyclines, especially doxycycline, have been reported to share 
the anti-inflammatory and neuroprotective properties of minocycline, they have 
not shown a similar efficacy in the same models (Garrido-Mesa et al., 2013) 
probably because of minocycline’s multiple targets, higher lipophilicity and 
capacity to cross the blood-brain barrier (BBB) compare to other tetracyclines. 
Erythromycin, a macrolide antibiotic, does not cross the BBB well and its 
concentrations in the cerebrospinal fluid are low (Sweetman, 2016). To the best 
of our knowledge, only minocycline has been investigated as a protective or 
adjuvant therapy for the treatment of schizophrenia. It is not expected, therefore, 
that exposure to other tetracyclines or erythromycin have a relationship with the 
incidence of SMI. To assess this in detail, however, we conducted an analysis 
where minocycline and the only tetracycline that crosses the BBB in a similar − 
although smaller  extent, doxycycline, were considered the drugs of interest. 
Results were consistent with those in the primary and sensitivity analyses. 
The observed relationship between gender and incidence of SMI is in keeping 
with the established literature which shows a higher incidence of SMI in young 
men compared with women (Castle et al., 2000), possibly due to a protective 
effect of estrogens on the emergence of SMI. Although this conclusion has not 
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been reached in some studies (Pedersen et al., 2014), we allowed for this potential 
beneficial effect and exposure to estrogens prescribed before the start of the 
follow-up period was considered a potential covariable. Exposure to this or other 
mentioned co-medications did not have a great impact on the results, possibly 
because of the low probability of adolescent individuals being exposed to these 
drugs. In the case of exposure to methylphenidate – commonly used to treat 
attention-deficit disorders (ADD) in children – the results showed a higher 
incidence of SMI in the sensitivity and doxycycline-minocycline analyses, while a 
relationship between exposure to antidepressants and later incidence of SMI was 
found in all our studies except for the sub-analysis for women. Although the 
studies described here were not designed for this purpose and give results that 
differ considerably between the different types of analyses (Supplementary Table 
7), our findings do suggest that individuals diagnosed with ADD may be 
diagnosed more often with SMI and that individuals with recorded prescriptions 
of methylphenidate or antidepressants during adolescence may have a higher 
incidence of SMI. 
Evidence from Animal Studies  
Adolescence is a relevant period of brain development characterized by dramatic 
changes in brain growth and connectivity through the creation of efficient neural 
pathways through synaptic refinement and it is, therefore, a period of 
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susceptibility to developmental disturbances induced by endogenous and 
exogenous factors (Bossong and Niesink, 2010), especially in 
neurodevelopmentally vulnerable subjects with genetic predisposition or 
prenatal infectious histories (Giovanoli et al., 2013). Mouse models showed that 
offspring exposed to combined prenatal immune challenge and peri-pubertal 
stress showed signs of central nervous system inflammation in the form of 
microglial overactivation (Giovanoli et al., 2016). Microglia are activated in 
response to brain injuries and an extensive list of immunological and pro-
inflammatory stimuli, leading to excessive and inappropriate release of toxic 
factors and pro-inflammatory cytokines (Takahashi et al., 2016). The relationship 
between psychiatric disorders and microglial activation in humans has been 
suggested by post-mortem brain and positron emission tomography (PET)-based 
studies (Takahashi et al., 2016). Exposure to anti-inflammatory and microglia-
activation inhibitory agents such as minocycline during adolescence has thus 
been proposed to have a potential preventative effect on the onset of these 
disorders and in the treatment of symptoms in early schizophrenia (Chaudhry et 
al., 2012; Giovanoli et al., 2016). 
Prior evidence for this preventative effect of minocycline comes, however, from a 
small number of animal studies and is not readily extrapolated to the clinical 
setting. Most of these studies used pharmacological models of schizophrenia 
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induced by dizocilpine maleate (Levkovitz et al., 2007; Zhang et al., 2007) or 
ketamine (Monte et al., 2013), which affect specific systems altered in 
schizophrenia (glutaminergic and dopaminergic system) and lead to models with 
cognitive deficits that resemble those seen in the disorder (Jones et al., 2011). 
Exposure to minocycline in these models is arranged close to time of 
administration of the inductive agents and so these experiments are of limited 
value in assessment of the long-term preventative effects of the drug. 
Schizophrenia and other SMI are multifactorial neurodevelopmental disorders 
influenced by both genetic and environmental factors that cannot be replicated 
by a pharmacological model only. Giovanoli et al. (2016) assessed the 
preventative potential of minocycline treatment in an environmental two-hit 
mouse model of schizophrenia combining prenatal immune activation and peri-
pubertal stress in mice, with the oral pre-symptomatic administration of 
minocycline taking place 24 hours before and during exposure to stressors. 
Although this approach provides a more realistic model and can be a useful tool 
to advance our understanding of the etiological basis of the disease, it still 
presents limitations for the evaluation of the long-term effect of minocycline in 
the clinical setting. 
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Strength and Limitations of the Study 
Conducting a randomized clinical trial to assess the preventative effect of long-
term exposure to minocycline during adolescence on the incidence of SMI would 
lead to ethical and economic issues that would make it impracticable. The best 
approach to address this clinically relevant question is, therefore, the hypothesis-
driven study described in this paper (Suissa and Garbe, 2007). The study has been 
conducted as a prospective observation study were patients were switched from 
the control to the exposed cohort when they completed a minimum duration 
treatment with minocycline after a minimum duration treatment with an 
alternative drug. To avoid potential bias caused by patients contributing follow-
up time to both the control group and minocycline-exposed, we conducted a post-
hoc analysis using robust standard errors to account for patient clustering. 
Results remained similar and evidence of a protective effect of minocycline in 
SMI was not found. 
We acknowledge that some patients may have received minocycline or alternative 
treatment for acne before receiving a diagnosis for acne and these patients were 
excluded from our cohort analysis. We decided to include patients exposed to 
minocycline after a diagnosis for acne to increase comparability between the 
exposed and non-exposed group.  
The main limitations of this study are those related to use of electronic primary 
care data. Recorded prescriptions in the CPRD data do not guarantee patients’ 
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adherence to the treatment and exposure to the drug. We should also 
acknowledge that treatment with minocycline could be prescribed through routes 
not recorded in the CPRD, such as secondary care units. The large population and 
length of the study period, however, are likely to mitigate against systematic bias. 
The mean duration of continuous exposure to minocycline was 336 days (11 
months) and we should recognize the possibility that the preventative effect 
might only be seen after longer exposure periods. Several potential confounders 
were identified and we adjusted for these covariables in our final model. The 
comparison of baseline characteristics showed the similarity of the two cohorts 
and, therefore, a propensity score matching approach was not considered 
pertinent. Apart from the mentioned demographic and treatment covariables 
other aspects, such as somatic co-morbidities or parental mental disorders, 
should be considered in further studies which do not rely only on primary care 
data. Although this study assessed the preventative effect of minocycline before 
the onset of the disease, the beneficial effect of the add-on therapy of minocycline 
could not be evaluated. More research should be conducted, therefore, to provide 
insights on the role and biological basis of minocycline as an adjuvant therapy for 
SMI. Nevertheless, the findings described here represent a crucial contribution 
to the field, and the robustness of the study design, the large survey population, 
and the long study period ensure their reliability. The conclusions of this study 
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should be considered when conducting future research and especially when 
planning clinical interventions. 
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